Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoMix® 30 FlexPen® as Monotherapy, or in Combination With OHA, in Treatment of Type 2 Diabetic Patients in Routine Clinical Practice: A Post-Marketing Surveillance Study

NCT00715663 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00715663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00715663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoMix® 30 FlexPen® as Monotherapy, or in Combination With OHA, in Treatment of Type 2 Diabetic Patients in Routine Clinical Practice: A Post-Marketing Surveillance Study
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
February 28, 2007
Completion date
December 31, 2007
Enrollment
1,584 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

delivery systems, diabetes, diabetes mellitus, type 2